Skip to main content

Table 4 Studies investigating tissue angiogenic and angiostatic parameters in experimental models of pulmonary fibrosis

From: Angiogenesis in Interstitial Lung Diseases: a pathogenetic hallmark or a bystander?

Investigator (year) Model Studied Parameters Summary Limitations
Keane et al. 61(1999) BPF MIP-2 Increased levels of MIP-2 in BPF mice / Inhibition of angiogenesis and fibrosis with neutralizing Abs Model not representative of IPF
Keane et al. 62(1999) BPF CXCL10 Decreased CXCL10 levels / CXCL10 administration reduced BPF and angiogenic response Model not representative of IPF
Jiang et al. 65 (2004) BPF CXCR3 Regulation of BPF by CXCR3 Model not representative of IPF / Incomplete analysis of angiogenic network
Tager et al. 78 (2004) BPF CXCL10 Inhibition of BPF by CXCL10 Model not representative of IPF / Incomplete analysis of angiogenic network
Burdick et al. 63 (2005) BPF CXCL11 Systemic administration of CXCL11 inhibited BPF by altering aberrant vascular remodeling Model not representative of IPF / Incomplete analysis of angiogenic network
Belperio et al. 52 (2005) Murine BOS CXCL1, 2, 3 CXCR2, VEGF Increased CXCR2/CXCR2 ligands' levels / Unchanged levels of VEGF / Neutralization of CXCR2 attenuated angiogenesis and BOS Model has heterotopic positioning and discounts influence of adjacent airway mucosa
Hamada et al. 64 (2005) BPF VEGF, sflt-1 Anti-VEGF gene therapy attenuates lung injury and fibrosis in BPF mice Model not representative of IPF / Incomplete analysis of angiogenic network
  1. Abbreviations: BPF: Bleomycin-induced pulmonary fibrosis, IPF: Idiopathic pulmonary fibrosis, VEGF: Vascular endothelial growth factor